JPMorgan Double Downgrades Absci Corp. (ABSI) to Underweight

Go back to JPMorgan Double Downgrades Absci Corp. (ABSI) to Underweight

Absci Reports Second Quarter 2022 Financial Results and Business Update

August 11, 2022 8:00 AM EDT

Exceeded annual Active Program guidance with ten programs signed year-to-date

Executed strategic reorganization to extend cash runway into late-2025

VANCOUVER, Wash. and NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended June 30, 2022.

"As we pass the halfway point of 2022, our team continues to make excellent progress toward... More

Absci Reports Second Quarter 2022 Financial Results and Business Update

August 11, 2022 8:00 AM EDT

Exceeded annual Active Program guidance with ten programs signed year-to-date

Executed strategic reorganization to extend cash runway into late-2025

VANCOUVER, Wash. and NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended June 30, 2022.

"As we pass the halfway point of 2022, our team continues to make excellent progress... More